We are analyzing https://link.springer.com/article/10.1007/s10585-015-9697-2.

Title:
Pattern of metastasis and outcome in patients with breast cancer | Clinical & Experimental Metastasis
Description:
There is growing evidence about differences in metastatic spread among breast cancer (BC) biologic subtypes (BS). Aim of this study was to analyze the pattern of metastasization according to BS and to explore the corresponding prognosis. A series of 544 consecutive patients receiving anticancer therapy for metastatic BC from 2004 to 2013, was analyzed. BS were defined by immunohistochemistry according to St Gallen 2013 criteria. Association between BS and the different distant localizations was analyzed. Prognosis was described in terms of overall survival (OS), progression free survival (PFS) and post progression survival (PPS). Results were reported taking luminal A BC as reference. Triple negative BC showed a higher tropism for lung (OR 4.30 95 % CI 1.41–13.1), while non luminal HER2 subtype was associated with a higher rate of liver metastases (OR 3.61 95 % CI 1.36–9.58). All subtypes were associated with a lower risk of bone-only localization. Central nervous system (CNS) involvement was more common in HER2 positive BC (OR 6.3, 95 % CI 1.08–36.66). Liver, lung and CNS involvement influenced negatively OS (HR 1.64, 95 % CI 1.29–2.07; HR 1.49, 95 % CI 1.18–1.90; HR 2.891, 95 % CI 1.85–4.51, respectively) and PFS (HR 1.39, 95 % CI 1.13–1.71; HR 1.26, 95 % CI 1.02–1.55; HR 1.75, 95 % CI 1.12–2.71, respectively). Multivariate analysis confirmed liver involvement as independent predictor of worse OS (HR 1.64, 95 % CI 1.15–2.34). Stratification by metastatic pattern showed significant differences in terms of PPS but not in terms of PFS. The study suggests that BS may be characterized by typical patterns of metastatic spread and have different impact on clinical outcome.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

cancer, breast, article, pubmed, google, scholar, metastatic, cas, metastasis, patients, oncol, outcome, subtypes, central, clin, gerratana, puglisi, metastases, access, privacy, cookies, content, clinical, survival, patterns, treatment, publish, research, search, pattern, bonotto, spread, study, prognosis, terms, liver, risk, rev, author, udine, data, information, log, journal, january, fanotto, minisini, explore, differences, distant,

Topics {✒️}

month download article/chapter her2-overexpressing breast cancer early-stage breast cancer central nervous system lymph node-negative disease full article pdf metastatic breast cancer her2 positive bc privacy choices/manage cookies early breast cancer prognostic factors relapsed breast cancer breast cancer classification clinical parameters influencing estrogen receptor status breast cancer subtypes luminal her2 subtype global cancer statistics breast cancer patients clin exp metastasis nationwide cohort study european economic area scope submit manuscript reported taking luminal protein expression predict real-world scenario breast conservation treatment conditions privacy policy metastatic spread bone metastasis article log progression free survival post progression survival accepting optional cookies liver metastases risk factors loco-regional treatment immunohistochemically defined luminal breast cancer article cite clinical outcome journal finder publish prognostic significance author information authors article gerratana distant metastases check access instant access measures metastatic bc

Questions {❓}

Puglisi F, Fontanella C, Numico G et al (2014) Follow-up of patients with early breast cancer: is it time to rewrite the story?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Pattern of metastasis and outcome in patients with breast cancer
         description:There is growing evidence about differences in metastatic spread among breast cancer (BC) biologic subtypes (BS). Aim of this study was to analyze the pattern of metastasization according to BS and to explore the corresponding prognosis. A series of 544 consecutive patients receiving anticancer therapy for metastatic BC from 2004 to 2013, was analyzed. BS were defined by immunohistochemistry according to St Gallen 2013 criteria. Association between BS and the different distant localizations was analyzed. Prognosis was described in terms of overall survival (OS), progression free survival (PFS) and post progression survival (PPS). Results were reported taking luminal A BC as reference. Triple negative BC showed a higher tropism for lung (OR 4.30 95 % CI 1.41–13.1), while non luminal HER2 subtype was associated with a higher rate of liver metastases (OR 3.61 95 % CI 1.36–9.58). All subtypes were associated with a lower risk of bone-only localization. Central nervous system (CNS) involvement was more common in HER2 positive BC (OR 6.3, 95 % CI 1.08–36.66). Liver, lung and CNS involvement influenced negatively OS (HR 1.64, 95 % CI 1.29–2.07; HR 1.49, 95 % CI 1.18–1.90; HR 2.891, 95 % CI 1.85–4.51, respectively) and PFS (HR 1.39, 95 % CI 1.13–1.71; HR 1.26, 95 % CI 1.02–1.55; HR 1.75, 95 % CI 1.12–2.71, respectively). Multivariate analysis confirmed liver involvement as independent predictor of worse OS (HR 1.64, 95 % CI 1.15–2.34). Stratification by metastatic pattern showed significant differences in terms of PPS but not in terms of PFS. The study suggests that BS may be characterized by typical patterns of metastatic spread and have different impact on clinical outcome.
         datePublished:2015-01-29T00:00:00Z
         dateModified:2015-01-29T00:00:00Z
         pageStart:125
         pageEnd:133
         sameAs:https://doi.org/10.1007/s10585-015-9697-2
         keywords:
            Breast neoplasm
            Immunophenotype
            Metastatic spread
            Prognostic factors
            Outcome measures
            Cancer Research
            Biomedicine
            general
            Oncology
            Hematology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-015-9697-2/MediaObjects/10585_2015_9697_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-015-9697-2/MediaObjects/10585_2015_9697_Fig2_HTML.gif
         isPartOf:
            name:Clinical & Experimental Metastasis
            issn:
               1573-7276
               0262-0898
            volumeNumber:32
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Netherlands
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:L. Gerratana
               affiliation:
                     name:University Hospital of Udine
                     address:
                        name:Department of Oncology, University Hospital of Udine, Udine, Italy
                        type:PostalAddress
                     type:Organization
                     name:University of Udine
                     address:
                        name:Department of Medical and Biological Sciences, University of Udine, Udine, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:V. Fanotto
               affiliation:
                     name:University Hospital of Udine
                     address:
                        name:Department of Oncology, University Hospital of Udine, Udine, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Bonotto
               affiliation:
                     name:University Hospital of Udine
                     address:
                        name:Department of Oncology, University Hospital of Udine, Udine, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S. Bolzonello
               affiliation:
                     name:University Hospital of Udine
                     address:
                        name:Department of Oncology, University Hospital of Udine, Udine, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. M. Minisini
               affiliation:
                     name:University Hospital of Udine
                     address:
                        name:Department of Oncology, University Hospital of Udine, Udine, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:G. Fasola
               affiliation:
                     name:University Hospital of Udine
                     address:
                        name:Department of Oncology, University Hospital of Udine, Udine, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:F. Puglisi
               affiliation:
                     name:University Hospital of Udine
                     address:
                        name:Department of Oncology, University Hospital of Udine, Udine, Italy
                        type:PostalAddress
                     type:Organization
                     name:University of Udine
                     address:
                        name:Department of Medical and Biological Sciences, University of Udine, Udine, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Pattern of metastasis and outcome in patients with breast cancer
      description:There is growing evidence about differences in metastatic spread among breast cancer (BC) biologic subtypes (BS). Aim of this study was to analyze the pattern of metastasization according to BS and to explore the corresponding prognosis. A series of 544 consecutive patients receiving anticancer therapy for metastatic BC from 2004 to 2013, was analyzed. BS were defined by immunohistochemistry according to St Gallen 2013 criteria. Association between BS and the different distant localizations was analyzed. Prognosis was described in terms of overall survival (OS), progression free survival (PFS) and post progression survival (PPS). Results were reported taking luminal A BC as reference. Triple negative BC showed a higher tropism for lung (OR 4.30 95 % CI 1.41–13.1), while non luminal HER2 subtype was associated with a higher rate of liver metastases (OR 3.61 95 % CI 1.36–9.58). All subtypes were associated with a lower risk of bone-only localization. Central nervous system (CNS) involvement was more common in HER2 positive BC (OR 6.3, 95 % CI 1.08–36.66). Liver, lung and CNS involvement influenced negatively OS (HR 1.64, 95 % CI 1.29–2.07; HR 1.49, 95 % CI 1.18–1.90; HR 2.891, 95 % CI 1.85–4.51, respectively) and PFS (HR 1.39, 95 % CI 1.13–1.71; HR 1.26, 95 % CI 1.02–1.55; HR 1.75, 95 % CI 1.12–2.71, respectively). Multivariate analysis confirmed liver involvement as independent predictor of worse OS (HR 1.64, 95 % CI 1.15–2.34). Stratification by metastatic pattern showed significant differences in terms of PPS but not in terms of PFS. The study suggests that BS may be characterized by typical patterns of metastatic spread and have different impact on clinical outcome.
      datePublished:2015-01-29T00:00:00Z
      dateModified:2015-01-29T00:00:00Z
      pageStart:125
      pageEnd:133
      sameAs:https://doi.org/10.1007/s10585-015-9697-2
      keywords:
         Breast neoplasm
         Immunophenotype
         Metastatic spread
         Prognostic factors
         Outcome measures
         Cancer Research
         Biomedicine
         general
         Oncology
         Hematology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-015-9697-2/MediaObjects/10585_2015_9697_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10585-015-9697-2/MediaObjects/10585_2015_9697_Fig2_HTML.gif
      isPartOf:
         name:Clinical & Experimental Metastasis
         issn:
            1573-7276
            0262-0898
         volumeNumber:32
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Netherlands
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:L. Gerratana
            affiliation:
                  name:University Hospital of Udine
                  address:
                     name:Department of Oncology, University Hospital of Udine, Udine, Italy
                     type:PostalAddress
                  type:Organization
                  name:University of Udine
                  address:
                     name:Department of Medical and Biological Sciences, University of Udine, Udine, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:V. Fanotto
            affiliation:
                  name:University Hospital of Udine
                  address:
                     name:Department of Oncology, University Hospital of Udine, Udine, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Bonotto
            affiliation:
                  name:University Hospital of Udine
                  address:
                     name:Department of Oncology, University Hospital of Udine, Udine, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S. Bolzonello
            affiliation:
                  name:University Hospital of Udine
                  address:
                     name:Department of Oncology, University Hospital of Udine, Udine, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. M. Minisini
            affiliation:
                  name:University Hospital of Udine
                  address:
                     name:Department of Oncology, University Hospital of Udine, Udine, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:G. Fasola
            affiliation:
                  name:University Hospital of Udine
                  address:
                     name:Department of Oncology, University Hospital of Udine, Udine, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:F. Puglisi
            affiliation:
                  name:University Hospital of Udine
                  address:
                     name:Department of Oncology, University Hospital of Udine, Udine, Italy
                     type:PostalAddress
                  type:Organization
                  name:University of Udine
                  address:
                     name:Department of Medical and Biological Sciences, University of Udine, Udine, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Clinical & Experimental Metastasis
      issn:
         1573-7276
         0262-0898
      volumeNumber:32
Organization:
      name:Springer Netherlands
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University Hospital of Udine
      address:
         name:Department of Oncology, University Hospital of Udine, Udine, Italy
         type:PostalAddress
      name:University of Udine
      address:
         name:Department of Medical and Biological Sciences, University of Udine, Udine, Italy
         type:PostalAddress
      name:University Hospital of Udine
      address:
         name:Department of Oncology, University Hospital of Udine, Udine, Italy
         type:PostalAddress
      name:University Hospital of Udine
      address:
         name:Department of Oncology, University Hospital of Udine, Udine, Italy
         type:PostalAddress
      name:University Hospital of Udine
      address:
         name:Department of Oncology, University Hospital of Udine, Udine, Italy
         type:PostalAddress
      name:University Hospital of Udine
      address:
         name:Department of Oncology, University Hospital of Udine, Udine, Italy
         type:PostalAddress
      name:University Hospital of Udine
      address:
         name:Department of Oncology, University Hospital of Udine, Udine, Italy
         type:PostalAddress
      name:University Hospital of Udine
      address:
         name:Department of Oncology, University Hospital of Udine, Udine, Italy
         type:PostalAddress
      name:University of Udine
      address:
         name:Department of Medical and Biological Sciences, University of Udine, Udine, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:L. Gerratana
      affiliation:
            name:University Hospital of Udine
            address:
               name:Department of Oncology, University Hospital of Udine, Udine, Italy
               type:PostalAddress
            type:Organization
            name:University of Udine
            address:
               name:Department of Medical and Biological Sciences, University of Udine, Udine, Italy
               type:PostalAddress
            type:Organization
      name:V. Fanotto
      affiliation:
            name:University Hospital of Udine
            address:
               name:Department of Oncology, University Hospital of Udine, Udine, Italy
               type:PostalAddress
            type:Organization
      name:M. Bonotto
      affiliation:
            name:University Hospital of Udine
            address:
               name:Department of Oncology, University Hospital of Udine, Udine, Italy
               type:PostalAddress
            type:Organization
      name:S. Bolzonello
      affiliation:
            name:University Hospital of Udine
            address:
               name:Department of Oncology, University Hospital of Udine, Udine, Italy
               type:PostalAddress
            type:Organization
      name:A. M. Minisini
      affiliation:
            name:University Hospital of Udine
            address:
               name:Department of Oncology, University Hospital of Udine, Udine, Italy
               type:PostalAddress
            type:Organization
      name:G. Fasola
      affiliation:
            name:University Hospital of Udine
            address:
               name:Department of Oncology, University Hospital of Udine, Udine, Italy
               type:PostalAddress
            type:Organization
      name:F. Puglisi
      affiliation:
            name:University Hospital of Udine
            address:
               name:Department of Oncology, University Hospital of Udine, Udine, Italy
               type:PostalAddress
            type:Organization
            name:University of Udine
            address:
               name:Department of Medical and Biological Sciences, University of Udine, Udine, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Oncology, University Hospital of Udine, Udine, Italy
      name:Department of Medical and Biological Sciences, University of Udine, Udine, Italy
      name:Department of Oncology, University Hospital of Udine, Udine, Italy
      name:Department of Oncology, University Hospital of Udine, Udine, Italy
      name:Department of Oncology, University Hospital of Udine, Udine, Italy
      name:Department of Oncology, University Hospital of Udine, Udine, Italy
      name:Department of Oncology, University Hospital of Udine, Udine, Italy
      name:Department of Oncology, University Hospital of Udine, Udine, Italy
      name:Department of Medical and Biological Sciences, University of Udine, Udine, Italy
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(115)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.19s.

LINK . SPRINGER . COM {}